Sodium Bicarbonate in 5% Dextrose Injection Lacks Sterility Assurance
SterRx is recalling 2,886 bags of Sodium Bicarbonate in 5% Dextrose Injection nationwide due to lack of assurance of sterility. The affected product may pose a risk to patients who receive this intravenous medication.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: This is an FDA Class II recall of an injectable pharmaceutical product with a sterility defect. Lack of sterility assurance in intravenous medications poses a direct risk of serious infection and adverse health consequences, meeting the criteria for Severe classification.
Plain-English summary
SterRx, LLC is recalling Sodium Bicarbonate in 5% Dextrose Injection (NDC 70324-326-03) distributed nationwide. The recall affects 2,886 bags manufactured by SterRx and distributed across the United States.
The reason for the recall is lack of assurance of sterility. This injectable drug product is required to meet strict sterility standards to ensure patient safety when administered intravenously.
Patients who have received this product should contact their healthcare provider. Healthcare providers should not distribute remaining units and should quarantine and return affected stock. The recalled product was distributed to healthcare facilities nationwide.
The recalled product
- Product
- Sodium Bicarbonate in 5% Dextrose Injection, Rx Only, SterRx, 141 Idaho Ave., Plattsburgh, NY 12903, NDC 70324-326-03
- Manufacturer
- SterRx, LLC
- Hazard
- sterility-assurance
- contamination-risk
- infection-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- S20459/BMP 17-Nov-21 S20472/BMZ 18-Nov-21 S20473/BNA 18-Nov-21
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- ModerateGas-X Simethicone 125 mg softgels recall for incomplete labeling
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27